@article{119a71edb2a74e65a8f6a0f1043edd0e,
title = "Cost and predictors of lost productive time in chronic migraine and episodic migraine: Results from the American Migraine Prevalence and Prevention (AMPP) Study",
abstract = "Objective: To quantify the cost differences and predictors of lost productive time (LPT) in persons with chronic migraine (CM) and episodic migraine (EM). Methods: The American Migraine Prevalence and Prevention (AMPP) study is a US national longitudinal survey of severe headache. Cost estimates were obtained via U.S. Census income data. To elucidate the unique predictors of LPT, the optimal distribution for modeling was determined. Zero inflation models for LPT were predicted from sociodemographics, headache features, characteristics and disability, medication use, and depression. The interaction between headache status and age was the primary effect of interest. Results: The eligible sample included 6329 persons with EM and 374 persons with CM. Men with CM aged 45 to 54 years cost employers nearly $200 per week more than do their EM counterparts. Likewise, for women, costs were higher for CM, with the cost differential between EM and CM being $90 per week. After comprehensive adjustment, increases in LPT with age were significantly higher in CM than in EM (rate ratio 1.03; 95% confidence interval 1.01-1.05). When age was recoded to a decade, metric rates of LPT increased 25% more per decade for CM than for EM (rate ratio 1.25; 95% confidence interval 1.004-1.5). Conclusions: LPT is more costly and increases more rapidly for those with CM than for those with EM as age increases.",
keywords = "absenteeism, chronic migraine, cost, episodic migraine, lost productive time, migraine, presenteeism",
author = "Daniel Serrano and Manack, {Aubrey N.} and Reed, {Michael L.} and Buse, {Dawn C.} and Varon, {Sepideh F.} and Lipton, {Richard B.}",
note = "Funding Information: Conflicts of interest: Daniel Serrano has received grant support from The National Headache Foundation via funding from Allergan Pharmaceuticals, GlaxoSmithKline, ENDO Pharmaceuticals, MAP Pharmaceuticals, OrthoMcNeil, and Merck, Inc., for data collection and/or analysis of the AMPP data set. Aubrey N. Manack is a full-time employee of Allergan, Inc. Michael L. Reed has received grant support from the National Headache Foundation via funding from Allergan Pharmaceuticals, GlaxoSmithKline, ENDO Pharmaceuticals, MAP Pharmaceuticals, Novartis, OrthoMcNeil, and Merck, Inc., for data collection and/or analysis of the AMPP data set. Dawn C. Buse has acted as a consultant and/or received research funding from Allergan Pharmaceuticals, ENDO Pharmaceuticals, Iroko Pharmaceuticals, MAP Pharmaceuticals, and Merck, Inc. Sepideh F. Varon is a full-time employee of Allergan, Inc. Richard B. Lipton has received grants from Allergan Pharmaceuticals, Endo Pharmaceuticals, GlaxoSmithKline, Minster, Merck, Inc., Neuralieve, Novartis, OrthoMcNeil, Pfizer, the National Headache Foundation, and the National Institutes of Health. He has received honoraria from Allergan Pharmaceuticals, AstraZeneca, Endo Pharmaceuticals, GlaxoSmithKline, MAP, Merck, Inc., Novartis, OrthoMcNeil, and Pfizer Funding Information: Source of financial support: The AMPP study was funded by a grant to the National Headache Foundation by Ortho-McNeil Neurologics, Inc., Titusville, NJ. Supplemental funding and support for this manuscript was provided through a grant to the National Headache Foundation by Allergan, Inc., Irvine, CA. ",
year = "2013",
month = jan,
doi = "10.1016/j.jval.2012.08.2212",
language = "English (US)",
volume = "16",
pages = "31--38",
journal = "Value in Health",
issn = "1098-3015",
publisher = "Elsevier Limited",
number = "1",
}